128 related articles for article (PubMed ID: 35587469)
1. Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice.
Belouzard S; Machelart A; Sencio V; Vausselin T; Hoffmann E; Deboosere N; Rouillé Y; Desmarets L; Séron K; Danneels A; Robil C; Belloy L; Moreau C; Piveteau C; Biela A; Vandeputte A; Heumel S; Deruyter L; Dumont J; Leroux F; Engelmann I; Alidjinou EK; Hober D; Brodin P; Beghyn T; Trottein F; Deprez B; Dubuisson J
PLoS Pathog; 2022 May; 18(5):e1010498. PubMed ID: 35587469
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
3. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
5. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
6. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
9. Lectin from
Auth J; Fröba M; Große M; Rauch P; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Dolischka A; Prieschl-Grassauer E; Setz C; Schubert U
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638545
[TBL] [Abstract][Full Text] [Related]
10. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
Chan SW; Shafi T; Ford RC
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
[TBL] [Abstract][Full Text] [Related]
12. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19.
de Almeida Marques DP; Andrade LAF; Reis EVS; Clarindo FA; Moraes TFS; Lourenço KL; De Barros WA; Costa NEM; Andrade LM; Lopes-Ribeiro Á; Coêlho Maciel MS; Corrêa-Dias LC; de Almeida IN; Arantes TS; Litwinski VCV; de Oliveira LC; Serafim MSM; Maltarollo VG; Guatimosim SC; Silva MM; Tsuji M; Ferreira RS; Barreto LV; Barbosa-Stancioli EF; da Fonseca FG; De Fátima Â; Coelho-Dos-Reis JGA
Virus Res; 2024 Feb; 340():199291. PubMed ID: 38065303
[TBL] [Abstract][Full Text] [Related]
13. Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms.
Marín-Palma D; Tabares-Guevara JH; Zapata-Cardona MI; Flórez-Álvarez L; Yepes LM; Rugeles MT; Zapata-Builes W; Hernandez JC; Taborda NA
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833991
[TBL] [Abstract][Full Text] [Related]
14. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Salas Rojas M; Silva Garcia R; Bini E; Pérez de la Cruz V; León Contreras JC; Hernández Pando R; Bastida Gonzalez F; Davila-Gonzalez E; Orozco Morales M; Gamboa Domínguez A; Sotelo J; Pineda B
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477376
[TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
16. Losartan Inhibits SARS-CoV-2 Replication in Vitro.
Nejat R; Sadr AS; Freitas B; Crabttree J; Pegan SD; Tripp RA; Najafi D
J Pharm Pharm Sci; 2021; 24():390-399. PubMed ID: 34319871
[TBL] [Abstract][Full Text] [Related]
17. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
20. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
